RESUMO
Objective: To explore influence of short-term intervention of different doses rosuvastatin on plasma levels of thrombomodulin (TM) and high sensitive C reactive protein (hsCRP) in patients with acute coronary syndrome (ACS). Methods: A total of 32 ACS patients were enrolled, randomly and equally divided into rosuvastatin 10mg group and rosuvastatin 20mg group, and another 16 patients without coronary heart disease were enrolled as normal control group. Enzyme linked immunosorbent assay (ELISA) was used to measure plasma levels of TM and hsCRP in two rosuvastatin groups before and after treatment and in normal control group at admission. Adverse drug reactions and incidence rates of cardiovascular events within one month were observed in two rosuvastatin groups. Results: Plasma levels of TM and hsCRP in two groups of ACS patients were both significantly higher than those of normal control group before treatment, P0.05); compared with rosuvastatin 10mg group, there was significant decrease in incidence rate of major adverse cardiovascular events（MACE）: Relapse angina pectoris (62.50% vs. 18.75%, P<0.01) in rosuvastatin 20mg group. Conclusions: Early intensive statins medication （rosuvastatin 20mg）can decrease plasma levels of thrombomodulin and high sensitive C reactive protein, and rosuvastatin 20mg/d can effectively decrease incidence rate of cardiovascular events without significant increase incidence rate of adverse drug reactions in ACS patients.